Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Tara C. Gangadhar Clear advanced filters

  • Prognostic and predictive markers in colon cancer might help define which patients with stage II disease are likely to benefit from adjuvant therapy. In this Review, Tara Gangadhar and Richard Schilsky discuss the recent clinical development of such markers, including microsatellite instability and 18q loss of heterozygosity. Further validation of these markers could potentially lead to the individualization of adjuvant therapy in colon cancer.

    • Tara Gangadhar
    • Richard L. Schilsky
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 7, P: 318-325

  • Novel approaches for cancer therapy take advantage of the modulation of the immune system. Immunotherapy is however associated with a number of adverse effects and clinicians will need to become familiar with recognizing and managing them. In this Review the authors describes the toxicity profiles for various anticancer therapies based on immunomodulatory agents.

    • Tara C. Gangadhar
    • Robert H. Vonderheide
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 11, P: 91-99

  • In this study, involving melanoma patients and a mouse model for melanoma, an optimal anti-tumour response was induced by using a combination of radiation with anti-CTLA4 and anti-PD-L1 antibody therapies, each attacking the tumour from a different angle.

    • Christina Twyman-Saint Victor
    • Andrew J. Rech
    • Andy J. Minn
    Research
    Nature
    Volume: 520, P: 373-377